Published on GHDx (https://ghdx.healthdata.org)

Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial)

General Info

Geography 
United Kingdom (GBR)
Coverage type 
Country
Time period covered 
January, 2008 - December, 2010
Data type
Scientific literature
Keywords 
Alzheimer's disease and other dementias

Citation

Authors 
Knapp M, King D, Romeo R, Adams J, Baldwin A, Ballard C, Banerjee S, Barber R, Bentham P, Brown RG, Burns A, Dening T, Findlay D, Holmes C, Johnson T, Jones R, Katona C, Lindesay J, Macharouthu A, McKeith I, McShane R, O'Brien JT, Phillips PPJ, Sheehan B, Howard R
Journal 
Int J Geriatr Psychiatry
Pages 
1205-1216
Publication year 
2017
Suggested citation 
Knapp M, King D, Romeo R, Adams J, Baldwin A, Ballard C, Banerjee S, Barber R, Bentham P, Brown RG, Burns A, Dening T, Findlay D, Holmes C, Johnson T, Jones R, Katona C, Lindesay J, Macharouthu A, McKeith I, McShane R, O'Brien JT, Phillips PPJ, Sheehan B, Howard R. Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial). Int J Geriatr Psychiatry. 2017; 32(12): 1205-1216.
Source URL:https://ghdx.healthdata.org/record/cost-effectiveness-donepezil-and-memantine-moderate-severe-alzheimers-disease-domino-ad-trial#comment-0